This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Erbs, P. Articles by Mehtali, M. Search for Related Content PubMed PubMed Citation Articles by Erbs, P. Articles by Mehtali, M.

In Vivo Cancer Gene Therapy by Adenovirus-mediated Transfer of a Bifunctional Yeast Cytosine Deaminase/Uracil Phosphoribosyltransferase Fusion Gene

Transgene S.A., 67082 Strasbourg Cedex, France [P. E., E. R., J. K., P. L., Y. P.]; Laboratoire de Génétique, Centre National de la Recherche Scientifique, UPR 9003, Institut de Recherche contre les Cancers de l’Appareil Digestif, Hôpital Civil, 67091 Strasbourg Cedex, France [F. E., R. J.]; and IntroGene BV, 2301 CA Leiden, the Netherlands [M. M.]

Direct transfer of prodrug activation systems into tumors was demonstrated to be an attractive method for the selective in vivo elimination of tumor cells. However, most current suicide gene therapy strategies are still handicapped by a poor efficiency of in vivo gene transfer and a limited bystander cell killing effect. In this study, we describe a novel and highly potent suicide gene derived from the Saccharomyces cerevisiae cytosine deaminase (FCY1) and uracil phosphoribosyltransferase genes (FUR1). This suicide gene, designated FCU1, encodes a bifunctional chimeric protein that combines the enzymatic activities of FCY1 and FUR1 and efficiently catalyzes the direct conversion of 5-FC, a nontoxic antifungal agent, into the toxic metabolites 5-fluorouracil and 5-fluorouridine-5'-monophosphate, thus bypassing the natural resistance of certain human tumor cells to 5-fluorouracil. Unexpectedly, although the uracil phosphoribosyltransferase activity of FCU1 was equivalent to that encoded by FUR1, its cytosine deaminase activity was 100-fold higher than the one encoded by FCY1. As a consequence, tumor cells transduced with an adenovirus expressing FCU1 (Ad-FCU1) were sensitive to concentrations of 5-FC 1000-fold lower than the ones used for cells transduced with a vector expressing FCY1 (Ad-FCY1). Furthermore, bystander cell killing was also more effective in cells transduced with Ad-FCU1 than in cultures infected with Ad-FCY1 or Ad-FUR1, alone or in combination. Finally, intratumoral injections of Ad-FCU1 into allo- or xenogeneic tumors implanted s.c. into mice, with concomitant systemic administration of 5-FC, led to substantial delays in tumor growth. These unique properties make of the FCU1/5-FC prodrug activation system a novel and powerful candidate for cancer gene therapy strategies.

This article has been cited by other articles:

				Z. Li, Y. Fortin, and S.-H. Shen Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries Nucleic Acids Res., January 1, 2009; 37(1): e8 - e8. [Abstract] [Full Text] [PDF]

				L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy Cancer Res., July 1, 2007; 67(13): 6304 - 6313. [Abstract] [Full Text] [PDF]

				M. L. Ramnaraine, W. E. Mathews, J. M. Donohue, C. M. Lynch, M. J. Goblirsch, and D. R. Clohisy Osteoclasts Direct Bystander Killing of Bone Cancer. Cancer Res., November 15, 2006; 66(22): 10929 - 10935. [Abstract] [Full Text] [PDF]

				J. A. M. Braks, B. Franke-Fayard, H. Kroeze, C. J. Janse, and A. P. Waters Development and application of a positive-negative selectable marker system for use in reverse genetics in Plasmodium Nucleic Acids Res., March 14, 2006; 34(5): e39 - e39. [Abstract] [Full Text] [PDF]

				B. Acres, M. Gantzer, C. Remy, N. Futin, N. Accart, O. Chaloin, J. Hoebeke, J.-M. Balloul, and S. Paul Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity Cancer Res., October 15, 2005; 65(20): 9536 - 9546. [Abstract] [Full Text] [PDF]

				M. Porosnicu, A. Mian, and G. N. Barber The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus Is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene Cancer Res., December 1, 2003; 63(23): 8366 - 8376. [Abstract] [Full Text] [PDF]

				C. R. Miller, C. R. Williams, D. J. Buchsbaum, and G. Y. Gillespie Intratumoral 5-Fluorouracil Produced by Cytosine Deaminase/5-Fluorocytosine Gene Therapy Is Effective for Experimental Human Glioblastomas Cancer Res., February 1, 2002; 62(3): 773 - 780. [Abstract] [Full Text] [PDF]

				D. Nanda, R. Vogels, M. Havenga, C. J. Avezaat, A. Bout, and P. S. Smitt Treatment of Malignant Gliomas with a Replicating Adenoviral Vector Expressing Herpes Simplex Virus-Thymidine Kinase Cancer Res., December 1, 2001; 61(24): 8743 - 8750. [Abstract] [Full Text] [PDF]